Best practice in the management of mild-to-moderately active ulcerative colitis and achieving maintenance of remission using mesalazine

被引:9
|
作者
Munkholm, Pia [1 ]
Michetti, Pierre [3 ,4 ]
Probert, Chris S. [5 ]
Elkjaer, Margarita [2 ]
Marteau, Philippe [6 ,7 ]
机构
[1] Univ Copenhagen, Herlev Hosp, Med Sect, Gastrointestinal Unit, DK-2730 Herlev, Denmark
[2] Herlev Univ Hosp, Med Sect, Gastrointestinal Unit, DK-2730 Herlev, Denmark
[3] CHU Vaudois, Clin Source, Ctr Crohn & Colite, CH-1011 Lausanne, Switzerland
[4] CHU Vaudois, Serv Gastroenterol & Hepatol, CH-1011 Lausanne, Switzerland
[5] Univ Hosp Bristol, Bristol, Avon, England
[6] Hop Lariboisiere, AP HP, F-75475 Paris, France
[7] Univ Paris, F-75252 Paris, France
关键词
clinical practice; cost; mesalazine; quality of life; remission; ulcerative colitis; QUALITY-OF-LIFE; RELEASE ORAL MESALAMINE; 5-AMINOSALICYLIC ACID; DOUBLE-BLIND; COMBINATION THERAPY; TOPICAL MESALAZINE; RANDOMIZED-TRIAL; ENEMAS; METAANALYSIS; SUPPOSITORIES;
D O I
10.1097/MEG.0b013e32833944bf
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Optimizing treatment goals in ulcerative colitis requires recognizing the needs of patients. It is increasingly recognized that adapting treatment strategies aligned with patient needs can improve patient compliance and consequently minimize relapse rates. Tailoring of treatment strategies can improve not only patient quality of life, and decrease the number harmed by adverse events from more potent drugs, but can also save valuable healthcare costs by avoiding high-cost treatment interventions associated with acute ulcerative colitis. This review will consider several elements of mesalazine management from the patient perspective based on a range of clinical and patient-focused evidence. By highlighting patient preferences in disease management it is envisaged that this review will aid physicians to optimize treatment decisions with the different mesalazine preparations available. Eur J Gastroenterol Hepatol 22: 912-916 (C) 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins.
引用
收藏
页码:912 / 916
页数:5
相关论文
共 50 条
  • [1] MMX mesalazine for the induction of remission of mild-to-moderately active ulcerative colitis: efficacy and tolerability in specific patient subpopulations
    Lichtenstein, G. R.
    Kamm, M. A.
    Sandborn, W. J.
    Lyne, A.
    Joseph, R. E.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2008, 27 (11) : 1094 - 1102
  • [2] Prediction of Treatment Failures in Induction of Remission With Oral Mesalamine in Mild-to-Moderately Active Ulcerative Colitis
    Kruis, Wolfgang
    Mueller, Ralph
    Greinwald, Roland
    GASTROENTEROLOGY, 2012, 142 (05) : S205 - S205
  • [3] Quality of Life Improvements Attributed to Combination Therapy with Oral and Topical Mesalazine in Mild-to-Moderately Active Ulcerative Colitis
    Connolly, M. P.
    Poole, C. D.
    Currie, C. J.
    Marteau, P.
    Nielsen, S. K.
    DIGESTION, 2009, 80 (04) : 241 - 246
  • [4] The Probiotic Preparation, VSL#3 Induces Remission in Patients With Mild-to-Moderately Active Ulcerative Colitis
    Sood, Ajit
    Midha, Vandana
    Makharia, Govind K.
    Ahuja, Vineet
    Singal, Dinesh
    Goswami, Pooja
    Tandon, Rakesh K.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2009, 7 (11) : 1202 - 1209
  • [5] Combined oral and rectal mesalazine for the treatment of mild-to-moderately active ulcerative colitis: Rapid symptom resolution and improvements in quality of life
    Probert, Christopher S. J.
    Dignass, Axel U.
    Lindgren, Stefan
    Pool, Marco Oudkerk
    Marteau, Philippe
    JOURNAL OF CROHNS & COLITIS, 2014, 8 (03): : 200 - 207
  • [6] Impact of Synbiotic Therapy on the Quality of Life in Patients with Mild-to-Moderately Active Ulcerative Colitis
    Altun, Hulya Kamarli
    Yildiz, Emine Akal
    Akin, Mete
    JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES, 2022, 31 (04) : 417 - 423
  • [7] MMX™ MESALAZINE THERAPY INDUCES MUCOSAL HEALING IN PATIENTS WITH MILD-TO-MODERATELY ACTIVE ULCERATIVE COLITIS REGARDLESS OF ESTABLISHED OR NEWLY DIAGNOSED DISEASE
    Lichtenstein, G. R.
    Sandborn, W.
    Kamm, M. A.
    Solomon, D.
    Karlstadt, R.
    Barrett, K.
    Abhyankar, B.
    Joseph, R. E.
    GUT, 2009, 58 : A57 - A57
  • [8] An economic evaluation comparing concomitant oral and topical mesalazine versus oral mesalazine alone in mild-to-moderately active ulcerative colitis based on results from randomised controlled trial
    Connolly, Mark P.
    Nielsen, Sandy K.
    Currie, Craig J.
    Marteau, Philippe
    Probert, Chris S. J.
    Travis, Simon P. L.
    JOURNAL OF CROHNS & COLITIS, 2009, 3 (03): : 168 - 174
  • [9] Effects of synbiotic therapy in mild-to-moderately active ulcerative colitis: A randomized placebo-controlled study
    Altun, Hulya Kamarli
    Yildiz, Emine Akal
    Akin, Mete
    TURKISH JOURNAL OF GASTROENTEROLOGY, 2019, 30 (04): : 313 - 320
  • [10] The economics of mesalazine in active ulcerative colitis and maintenance in the Netherlands
    Connolly, M. P.
    Boersma, C.
    Oldenburg, B.
    NETHERLANDS JOURNAL OF MEDICINE, 2012, 70 (06): : 272 - 277